1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Suvanza Pharma, LLC

Suvanza Pharma, LLC

SUVZ
Suvanza Pharma, LLCUS flagOther OTC
0.00
USD
- -
- -
1.01MMarket Cap
Suvanza Pharma, LLC
SUVZ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
TTM
FRC
382.66
630.53
512.71
643.93
2.34
- -
15.62
0.02
0.61
- -
0.07
Revenue per Share
42
51
37
47.2
75
-206.76
-314.43
-151.95
-251.08
-165.21
-146.89
Basic EPS, GAAP
28
32.45
-18.5
-36.14
-168.75
-122.81
-139.7
-243.36
-166.17
-130
-111.58
Free Cash Flow per Basic Share
32.67
23.18
15.86
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
46.67
83.45
37
332.15
452.01
264.47
246.72
206.39
27.1
-51.6
-75.58
Book Value per Share
60.67
125.18
351.5
332.15
452.34
263.77
316.79
283.9
119.5
67.35
39.96
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
8
14
19
31
- -
- -
1
- -
- -
- -
- -
Sales/Revenue/Turnover
15.85
13.24
8.76
10.26
-1,400
- -
-703.68
-1,036,300
-42,888.24
- -
-223,171.43
Operating Margin (%)
- -
- -
- -
1
- -
1
1
- -
4
4
4
Depreciation Expense
1
1
1
2
3
-9
-16
-9
-21
-17
-15
Net Income, GAAP
35.71
35.29
33.33
37.75
33.56
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
10.98
8.09
7.22
7.33
3,200
- -
-2,012.83
-946,800
-40,905.88
- -
-220,142.86
Profit Margin (%)
1
2
12
15
17
11
16
7
5
2
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
3
13
16
19
12
16
18
10
7
4
Total Equity
- -
58.24
14.17
13.48
-5.12
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
78.57
87.5
26.12
18.19
-58.67
-131.93
-74.88
-276.1
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'02
Dec'02
Mar'03
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'02
Dec'02
Mar'03
Total Current Assets
5
3
2
Cash, Cash Equivalents & STI
5
2
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.18%
-30.88%
Free Cash Flow
- -
21.6%
-4.06%
Net Income, GAAP
- -
-49.45%
-19.3%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
- -
- -
- -
- -
- -
2002
- -
- -
- -
- -
- -
2003
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
-51.14
-60.78
-64.73
- -
-251.08
2002
-44.16
-55.82
-34.06
- -
-165.21
2003
-24.44
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2001
- -
- -
- -
- -
- -
2002
- -
- -
- -
- -
- -
2003
- -
- -
- -
- -
- -
Similar Companies
Pharming Group N.V. (PHGUF)
NeurAxis, Inc. (NRXS)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
AlphaTON Capital Corp. (ATON)
Silence Therapeutics plc (SLN.L)
Sarepta Therapeutics, Inc. (0L35.L)
Business
Suvanza Pharma, LLC (SUVZ) operates as an early-stage biotechnology company focused on developing advanced transdermal drug delivery systems for dermatological diseases; its primary product is RapiDerm, a proprietary skin drug delivery platform designed to enhance drug penetration for treating conditions including eczema, psoriasis, and other inflammatory skin disorders. The company offers research, development, and commercialization activities encompassing formulation development, preclinical studies, clinical trials, and regulatory efforts aimed at improving therapeutic outcomes and patient quality of life through innovative dermatology treatments. Founded in 2004 and headquartered in McClellan, California, with references to operations in Miami Beach, Florida, Suvanza targets pharmaceutical companies, dermatologists, and patients in the global dermatology market, seeking partnerships for product advancement and commercialization. Suvanza Pharma, LLC, formerly known as Hamilton PNG until its name change in March 2010 and previously associated with CenterSpan Communications Corporation, continues to prioritize R&D for its RapiDerm platform without reported recent acquisitions, funding rounds, or major strategic expansions in 2024 or 2025; the company maintains its focus on early-stage biotechnology operations in the dermatologic therapeutics segment.